Blockchain Registration Transaction Record
SignaBlok to Present Positive Preclinical Data on TREM-1 Inhibitor for Multiple Diseases at RIS and ATS Conference
SignaBlok, a biotech company, to unveil promising preclinical data on TREM-1 inhibitor for sepsis, ARDS, and PF at RIS and ATS Conference. Their innovative technology platform could transform treatment for severe inflammatory diseases.

This news matters as SignaBlok's innovative peptide therapy shows promise in treating severe inflammatory conditions. The potential of their technology platform to develop effective treatments with minimal risk of failure could revolutionize the approach to diseases like sepsis, ARDS, and PF, impacting patient outcomes and healthcare costs.
Blockchain | Details |
---|---|
Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
Transaction ID | 0xe8ee25454568d57d1a1374aefc4c9e92bc3edc26564b92023993e9beb44ac7a8 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | pondvvjO-27b5f04aacabe453412f7faabfd0f296 |